BLACK WEEKSVialer −15% · kit −10% · övrigt −5%med kodFri frakt inom Tyskland från €200

Den här sidan har översatts automatiskt och kan innehålla fel. Har du svenska som modersmål? Vi tar gärna emot din feedback och dina förbättringar.Skicka feedback

The Peptide Desk The Peptide Desk
Mazdutide, produktfoto
GLP-1

Mazdutide

GLP-1

  • Skickas från Tyskland

Beställning

Styckpris - Fri frakt inom Tyskland från 200 € under Black Weeks
  • DHL med spårning
  • Diskret förpackning

4.6 av 5 på Trustpilot73 omdömen

Söks även som: Mazdutid · LY3305677 · IBI362

I korthet

Mazdutide i siffror

Nyckeltalen från vårt lexikon.

Hela lexikonartikeln
Class
GLP-1 / glucagon dual agonistoxyntomodulin analogue
Half-life
Several daysweekly dose
Frequency
Once weeklysubcutaneous
Form
Lyophilised powderreconstituted with BAC water
Sizes
5 to 10 mg2 sizes in the shop

Det finns ännu ingen labbanalys för Mazdutide. Rösta på denLåt testa själv, vi betalar halvaAlla labbanalyser

Kunskap

Allt om Mazdutide

Bra att ha

Vad du behöver till den

Bakteriostatiskt vatten läggs automatiskt i din varukorg. Sprutor och sudd med ett klick.

Insulinsprutor

10 st. · 5.50 €

Spritsuddar

50 st. · 10 €

Hur mycket vatten?

Enheter på sprutan för din vialstorlek.

Öppna kalkylatorn →

FAQ

Vanliga frågor

Källor till varje svar: lexikonartikel

Har du fortfarande en fråga?

Skriv till oss, vårt team hjälper dig.

Is Mazdutide approved?

In China, yes. The first approval came in June 2025 for long-term weight management in obesity or overweight with a related condition, type 2 diabetes followed in September 2025. Mazdutide is not approved in the EU or the USA, ChEMBL lists phase 3 as the highest phase. The information here describes the state of research and is not a recommendation for use.

How does Mazdutide differ from Tirzepatide and Retatrutide?

The receptors. Mazdutide acts on GLP-1 and glucagon, Tirzepatide on GLP-1 and GIP, Retatrutide on all three. Mazdutide is derived from the gut hormone oxyntomodulin, which naturally addresses both receptors. A running trial with a higher dose compares it directly with Tirzepatide, there are no results yet.

What did the phase 3 trials show?

In GLORY-1 weight fell by 11.0 and 14.0 percent on average after 48 weeks, on placebo it rose by 0.3 percent. In GLORY-2 with a higher dose it was 16.7 versus 1.5 percent after 60 weeks. In type 2 diabetes HbA1c fell by 1.57 and 2.15 percentage points after 24 weeks (placebo 0.14). Against dulaglutide both doses were ahead for HbA1c and weight.

How long does Mazdutide stay in the body?

In the first phase 1b study in China the half-life was between 6.3 and 16.8 days. An attached fatty acid makes this possible. That fits one dose a week, which is how all trials give Mazdutide.

How high were the doses in trials?

The highest study dose was 16 mg per week, in a phase 1 study and a phase 2 trial in the USA. There weight fell by 18.1 percent after 32 weeks, but 20 percent stopped because of side effects. All trials raise the dose in steps over weeks. The entry describes the same principle: start low and only increase while there is no noticeable effect. This is not a dosing recommendation.

Which side effects were seen?

Mainly gastrointestinal effects, mostly mild to moderate. In GLORY-2 53.1 percent had vomiting, 46.9 percent nausea and 39.4 percent diarrhoea (placebo 1.3, 3.2 and 6.5 percent). In GLORY-1 only 0.5 to 1.5 percent stopped because of side effects. In an early study the complaints occurred mainly in the first dose levels.

Which trials are still running?

Four of the listed phase 3 trials are not finished yet: on fatty liver versus semaglutide, on sleep apnoea, in adolescents and on high blood pressure. Phase 2 trials are running on heart failure with obesity and on fatty liver with inflammation (MASH).

Relaterat

Relaterade produkter